One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial

By sjmartinez • June 7, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jun 5:ciad342. doi: 10.1093/cid/ciad342. Epub ahead of print. PMID: 37279602.

Tags: camostat, covid-19, Infectious Diseases, outpatient, phase 2, Publications, SARS-CoV-2

Immunotherapy for invasive Candida infections: Translating host-directed strategies into clinical practice

Sprute R, Singh S, Conti HR, Cornely OA, van de Veerdonk FL, Carvalho A, Ibrahim AS. Immunotherapy for invasive Candida infections: Translating host-directed strategies into[...]

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

Hoffman R, Watanabe M, Martínez E, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Lu[...]

PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV

Duarte MJ, Tien PC, Kuniholm MH, Ma Y, Thio CL, Hanna DB, Witt MD, Skvarca C, Brock J, French AL, Alcaide M, Floris-Moore M, Seaberg[...]